2,825,000 Shares in Eyepoint Pharmaceuticals, Inc. $EYPT Acquired by Commodore Capital LP

Commodore Capital LP acquired a new stake in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) in the 1st quarter, Holdings Channel.com reports. The fund acquired 2,825,000 shares of the company’s stock, valued at approximately $36,414,000. Eyepoint Pharmaceuticals makes up 2.1% of Commodore Capital LP’s portfolio, making the stock its 18th biggest position.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Suvretta Capital Management LLC lifted its stake in shares of Eyepoint Pharmaceuticals by 26.4% in the 4th quarter. Suvretta Capital Management LLC now owns 7,827,685 shares of the company’s stock valued at $143,012,000 after purchasing an additional 1,634,970 shares during the period. Adage Capital Partners GP L.L.C. boosted its stake in Eyepoint Pharmaceuticals by 9.7% in the second quarter. Adage Capital Partners GP L.L.C. now owns 6,800,000 shares of the company’s stock valued at $63,988,000 after acquiring an additional 600,000 shares during the last quarter. Federated Hermes Inc. raised its position in shares of Eyepoint Pharmaceuticals by 36.3% in the fourth quarter. Federated Hermes Inc. now owns 6,017,433 shares of the company’s stock valued at $109,938,000 after purchasing an additional 1,601,101 shares during the period. Franklin Resources Inc. grew its position in shares of Eyepoint Pharmaceuticals by 19.3% during the 4th quarter. Franklin Resources Inc. now owns 4,976,915 shares of the company’s stock valued at $90,928,000 after purchasing an additional 805,031 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Eyepoint Pharmaceuticals by 27.1% in the 4th quarter. Vanguard Group Inc. now owns 4,822,139 shares of the company’s stock worth $88,100,000 after buying an additional 1,027,623 shares during the period. Institutional investors and hedge funds own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Price Performance

Shares of EYPT opened at $12.19 on Monday. Eyepoint Pharmaceuticals, Inc. has a 1 year low of $9.40 and a 1 year high of $19.11. The company has a 50 day simple moving average of $13.19 and a two-hundred day simple moving average of $14.03. The firm has a market cap of $1.02 billion, a P/E ratio of -3.48 and a beta of 1.73.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its earnings results on Wednesday, May 6th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.79) by ($0.20). Eyepoint Pharmaceuticals had a negative return on equity of 110.54% and a negative net margin of 3,566.63%.The firm had revenue of $0.70 million during the quarter, compared to the consensus estimate of $0.35 million. On average, sell-side analysts anticipate that Eyepoint Pharmaceuticals, Inc. will post -3.3 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on EYPT. Guggenheim reaffirmed a “buy” rating and issued a $68.00 price target on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, June 24th. Cantor Fitzgerald started coverage on Eyepoint Pharmaceuticals in a report on Wednesday, July 8th. They set an “overweight” rating and a $47.00 price target on the stock. Stifel Nicolaus initiated coverage on Eyepoint Pharmaceuticals in a research report on Thursday, July 16th. They set a “buy” rating and a $40.00 price objective on the stock. Royal Bank Of Canada decreased their target price on Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.75.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.